000			01470 a2200421 4500
005			20250516071900.0
264		0	_c20121017
008			201210s 0 0 eng d
022			_a1432-1076
024	7		_a10.1007/s00431-011-1660-x _2doi
040			_aNLM _beng _cNLM
100	1		_aKleber, C J
245	0	0	_aUrinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. _h[electronic resource]
260			_bEuropean journal of pediatrics _cJun 2012
300			_a941-6 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdrenergic beta-Antagonists _xtherapeutic use
650	0	4	_aAge Factors
650	0	4	_aBiomarkers _xurine
650	0	4	_aCase-Control Studies
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHemangioma _xdrug therapy
650	0	4	_aHumans
650	0	4	_aInfant
650	0	4	_aMale
650	0	4	_aMatrix Metalloproteinase 2 _xurine
650	0	4	_aMatrix Metalloproteinase 9 _xurine
650	0	4	_aPropranolol _xtherapeutic use
650	0	4	_aTreatment Outcome
700	1		_aSpiess, A
700	1		_aKleber, J B
700	1		_aHinz, U
700	1		_aHolland-Cunz, S
700	1		_aWeiss, J
773	0		_tEuropean journal of pediatrics _gvol. 171 _gno. 6 _gp. 941-6
856	4	0	_uhttps://doi.org/10.1007/s00431-011-1660-x _zAvailable from publisher's website
999			_c21422812 _d21422812